These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 34036899)
1. Cell type-specific YAP1-WWTR1/TAZ transcriptional responses after autophagy perturbations are determined by levels of α-catenins (CTNNA1 and CTNNA3). Pavel M; Park SJ; Tanasa R; Rubinsztein DC Autophagy; 2021 Jul; 17(7):1788-1790. PubMed ID: 34036899 [TBL] [Abstract][Full Text] [Related]
2. Increased Park SJ; Frake RA; Rubinsztein DC Autophagy; 2023 Mar; 19(3):943-944. PubMed ID: 35822241 [TBL] [Abstract][Full Text] [Related]
3. α-Catenin levels determine direction of YAP/TAZ response to autophagy perturbation. Pavel M; Park SJ; Frake RA; Son SM; Manni MM; Bento CF; Renna M; Ricketts T; Menzies FM; Tanasa R; Rubinsztein DC Nat Commun; 2021 Mar; 12(1):1703. PubMed ID: 33731717 [TBL] [Abstract][Full Text] [Related]
4. A highly sensitive reporter system to monitor endogenous YAP1/TAZ activity and its application in various human cells. Hikasa H; Kawahara K; Inui M; Yasuki Y; Yamashita K; Otsubo K; Kitajima S; Nishio M; Arima K; Endo M; Taira M; Suzuki A Cancer Sci; 2024 Oct; 115(10):3370-3383. PubMed ID: 39155534 [TBL] [Abstract][Full Text] [Related]
5. The Hippo effector TAZ (WWTR1) transforms myoblasts and TAZ abundance is associated with reduced survival in embryonal rhabdomyosarcoma. Mohamed A; Sun C; De Mello V; Selfe J; Missiaglia E; Shipley J; Murray GI; Zammit PS; Wackerhage H J Pathol; 2016 Sep; 240(1):3-14. PubMed ID: 27184927 [TBL] [Abstract][Full Text] [Related]
6. Loss of Goto H; Nishio M; To Y; Oishi T; Miyachi Y; Maehama T; Nishina H; Akiyama H; Mak TW; Makii Y; Saito T; Yasoda A; Tsumaki N; Suzuki A Development; 2018 Mar; 145(6):. PubMed ID: 29511023 [TBL] [Abstract][Full Text] [Related]
7. Recurrent WWTR1 S89W mutations and Hippo pathway deregulation in clear cell carcinomas of the cervix. Kim SH; Basili T; Dopeso H; Da Cruz Paula A; Bi R; Issa Bhaloo S; Pareja F; Li Q; da Silva EM; Zhu Y; Hoang T; Selenica P; Murali R; Chan E; Wu M; Derakhshan F; Maroldi A; Hanlon E; Ferreira CG; Lapa E Silva JR; Abu-Rustum NR; Zamarin D; Chandarlapaty S; Matrai C; Yoon JY; Reis-Filho JS; Park KJ; Weigelt B J Pathol; 2022 Aug; 257(5):635-649. PubMed ID: 35411948 [TBL] [Abstract][Full Text] [Related]
8. Hippo pathway effectors YAP1/TAZ induce an EWS-FLI1-opposing gene signature and associate with disease progression in Ewing sarcoma. Rodríguez-Núñez P; Romero-Pérez L; Amaral AT; Puerto-Camacho P; Jordán C; Marcilla D; Grünewald TG; Alonso J; de Alava E; Díaz-Martín J J Pathol; 2020 Apr; 250(4):374-386. PubMed ID: 31880317 [TBL] [Abstract][Full Text] [Related]
9. Differential influence of YAP1 and TAZ on differentiation of intestinal epithelial cell: A review. Fallah S; Beaulieu JF Anat Rec (Hoboken); 2023 May; 306(5):1054-1061. PubMed ID: 35648375 [TBL] [Abstract][Full Text] [Related]
10. The Hippo Pathway as Drug Targets in Cancer Therapy and Regenerative Medicine. Nagashima S; Bao Y; Hata Y Curr Drug Targets; 2017; 18(4):447-454. PubMed ID: 26758663 [TBL] [Abstract][Full Text] [Related]
11. Zebrafish mutants and TEAD reporters reveal essential functions for Yap and Taz in posterior cardinal vein development. Astone M; Lai JKH; Dupont S; Stainier DYR; Argenton F; Vettori A Sci Rep; 2018 Jul; 8(1):10189. PubMed ID: 29976931 [TBL] [Abstract][Full Text] [Related]
13. TAZ and YAP are frequently activated oncoproteins in sarcomas. Fullenkamp CA; Hall SL; Jaber OI; Pakalniskis BL; Savage EC; Savage JM; Ofori-Amanfo GK; Lambertz AM; Ivins SD; Stipp CS; Miller BJ; Milhem MM; Tanas MR Oncotarget; 2016 May; 7(21):30094-108. PubMed ID: 27129148 [TBL] [Abstract][Full Text] [Related]
14. The complexity of biological control systems: An autophagy case study. Pavel M; Tanasa R; Park SJ; Rubinsztein DC Bioessays; 2022 Mar; 44(3):e2100224. PubMed ID: 35032045 [TBL] [Abstract][Full Text] [Related]
15. The N-terminal phosphodegron targets TAZ/WWTR1 protein for SCFβ-TrCP-dependent degradation in response to phosphatidylinositol 3-kinase inhibition. Huang W; Lv X; Liu C; Zha Z; Zhang H; Jiang Y; Xiong Y; Lei QY; Guan KL J Biol Chem; 2012 Jul; 287(31):26245-53. PubMed ID: 22692215 [TBL] [Abstract][Full Text] [Related]
16. An optogenetic method for interrogating YAP1 and TAZ nuclear-cytoplasmic shuttling. Dowbaj AM; Jenkins RP; Williamson D; Heddleston JM; Ciccarelli A; Fallesen T; Hahn KM; O'Dea RD; King JR; Montagner M; Sahai E J Cell Sci; 2021 Jul; 134(13):. PubMed ID: 34060624 [TBL] [Abstract][Full Text] [Related]
18. The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma. Kaneda A; Seike T; Danjo T; Nakajima T; Otsubo N; Yamaguchi D; Tsuji Y; Hamaguchi K; Yasunaga M; Nishiya Y; Suzuki M; Saito JI; Yatsunami R; Nakamura S; Sekido Y; Mori K Am J Cancer Res; 2020; 10(12):4399-4415. PubMed ID: 33415007 [TBL] [Abstract][Full Text] [Related]
19. CSE1L promotes nuclear accumulation of transcriptional coactivator TAZ and enhances invasiveness of human cancer cells. Nagashima S; Maruyama J; Honda K; Kondoh Y; Osada H; Nawa M; Nakahama KI; Ishigami-Yuasa M; Kagechika H; Sugimura H; Iwasa H; Arimoto-Matsuzaki K; Nishina H; Hata Y J Biol Chem; 2021 Jul; 297(1):100803. PubMed ID: 34022224 [TBL] [Abstract][Full Text] [Related]
20. Yap1/Taz are essential for the liver development in zebrafish. Yi X; Yu J; Ma C; Li L; Luo L; Li H; Ruan H; Huang H Biochem Biophys Res Commun; 2018 Sep; 503(1):131-137. PubMed ID: 29859190 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]